[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,692
  • Shares Outstanding, K 243,448
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,420 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.74
  • Price/Sales 114.22
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings $-0.09 on 08/14/26
  • Next Earnings Date 12/18/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 301.36% (+6.97%)
  • Historical Volatility 140.02%
  • IV Percentile 63%
  • IV Rank 30.80%
  • IV High 818.65% on 02/27/26
  • IV Low 71.16% on 08/26/26
  • Expected Move (DTE 16) 0.0085 (1.38%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 2,525
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 56,672
  • Open Int (30-Day) 85,733
  • Expected Range 0.6066 to 0.6236

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 3
  • High Estimate $-0.02
  • Low Estimate $-0.09
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) +72.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5900 +5.64%
on 08/24/26
1.1800 -47.18%
on 08/12/26
-0.3533 (-36.18%)
since 07/31/26
3-Month
0.5900 +5.64%
on 08/24/26
1.8800 -66.85%
on 06/22/26
-0.1903 (-23.39%)
since 06/02/26
52-Week
0.1611 +286.90%
on 03/24/26
2.5375 -75.44%
on 12/17/25
-0.2468 (-28.36%)
since 09/02/25

Most Recent Stories

More News
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans...

OTLK : 0.6228 (-0.05%)
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans...

OTLK : 0.6228 (-0.05%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Video webcast now available here

OTLK : 0.6228 (-0.05%)
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Video webcast now available  here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization...

OTLK : 0.6228 (-0.05%)
OTLKW : 0.03 (-1.96%)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?

AKTX : 9.70 (-6.46%)
ERNA : 4.72 (+8.39%)
OTLK : 0.6228 (-0.05%)
AIM : 0.2287 (-3.09%)
CNSP : 5.91 (+0.34%)
NVNO : 11.55 (+5.19%)
DARE : 0.7743 (+0.53%)
GRI : 1.9250 (+0.79%)
MBRX : 0.6831 (+5.09%)
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used

OTLK : 0.6228 (-0.05%)
AMD : 456.77 (-0.62%)
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy...

OTLK : 0.6228 (-0.05%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of...

OTLK : 0.6228 (-0.05%)
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization...

OTLK : 0.6228 (-0.05%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of...

OTLK : 0.6228 (-0.05%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 0.6641
2nd Resistance Point 0.6524
1st Resistance Point 0.6378
Last Price 0.6228
1st Support Level 0.6115
2nd Support Level 0.5998
3rd Support Level 0.5852

See More

52-Week High 2.5375
Fibonacci 61.8% 1.6297
Fibonacci 50% 1.3493
Fibonacci 38.2% 1.0689
Last Price 0.6228
52-Week Low 0.1611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.